Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

3.

Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G.

J Am Coll Cardiol. 2007 Mar 27;49(12):1272-8.

4.

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A.

J Am Coll Cardiol. 2009 Aug 4;54(6):558-65. doi: 10.1016/j.jacc.2009.05.028. Epub 2009 Jul 2.

5.

Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.

Yu XL, Zhang HJ, Ren SD, Geng J, Wu TT, Chen WQ, Ji XP, Zhong L, Ge ZM.

Coron Artery Dis. 2011 Mar;22(1):87-91. doi: 10.1097/MCA.0b013e328341baee.

PMID:
21169815
6.

Atorvastatin for reduction of myocardial damage during angioplasty trials.

Nusca A, Melfi R, Patti G, Di Sciascio G.

J Cardiovasc Med (Hagerstown). 2010 Oct;11(10):709-11. No abstract available.

PMID:
20815110
7.

[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].

Patti G, Pasceri V, Nusca A, Di Sciascio G.

Ital Heart J Suppl. 2005 Sep;6(9):553-60. Review. Italian.

PMID:
16281714
8.

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators.

Circulation. 2004 Aug 10;110(6):674-8. Epub 2004 Jul 26.

10.

Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.

Sun Y, Qi G, Gao Y, Zhang H, Pang X, Zhao W, Zhang Z.

Can J Cardiol. 2010 Nov;26(9):481-5.

11.
12.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
13.

Prevention of myocardial damage during coronary intervention.

Pasceri V, Patti G, Di Sciascio G.

Cardiovasc Hematol Disord Drug Targets. 2006 Jun;6(2):77-83.

PMID:
16787193
15.

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.

Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovicová L, Tesar D.

Am J Cardiol. 2009 Sep 1;104(5):630-3. doi: 10.1016/j.amjcard.2009.04.048. Epub 2009 Jun 24.

PMID:
19699335
17.

Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention.

Veselka J, Zemánek D, Hájek P, Malý M, Adlová R, Martinkovičová L, Tomašov P, Tesař D.

Am J Cardiol. 2011 May 1;107(9):1295-9. doi: 10.1016/j.amjcard.2010.12.040. Epub 2011 Feb 23.

PMID:
21349484
18.

Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.

Nusca A, Melfi R, Patti G, Sciascio GD.

Future Cardiol. 2010 Sep;6(5):579-89. doi: 10.2217/fca.10.77. Review.

PMID:
20932108
19.

Percutaneous coronary interventions and statins therapy.

Nusca A, Melfi R, Di Sciascio G.

Ther Adv Cardiovasc Dis. 2008 Apr;2(2):101-7. doi: 10.1177/1753944708089983. Review.

PMID:
19124413
20.

Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.

Kim MJ, Jeon DS, Gwon HC, Kim SJ, Chang K, Kim HS, Tahk SJ; Korean MUSTANG Investigators.

Clin Cardiol. 2012 Nov;35(11):700-6. doi: 10.1002/clc.22038. Epub 2012 Jul 23.

Supplemental Content

Support Center